NCT02561962View on ClinicalTrials.gov

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 20, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

April 21, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

AMG 224

Administered as an IV infusion.

Trial Locations (5)

3181

Research Site, Prahran

10065

Research Site, New York

77030

Research Site, Houston

90069

Research Site, West Hollywood

02114

Research Site, Boston

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY